Peter Lio, MD

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.

Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.

Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.